Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Crizotinib
Drug ID BADD_D00535
Description Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status Prescription
ATC Code L01ED01
DrugBank ID DB08865
KEGG ID D09731
MeSH ID D000077547
PubChem ID 11626560
TTD Drug ID D03ZBT
NDC Product Code 0069-8141; 53869-2231; 68724-1020; 0069-8140; 72969-115; 53869-2230
Synonyms Crizotinib | PF-02341066 | PF-2341066 | PF 2341066 | PF2341066 | PF 02341066 | PF02341066 | Xalkori
Chemical Information
Molecular Formula C21H22Cl2FN5O
CAS Registry Number 877399-52-5
SMILES CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bradycardia02.03.02.0020.013587%Not Available
Breast cancer21.05.01.003; 16.10.01.001--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchopulmonary aspergillosis11.03.01.002; 22.07.08.0010.000139%Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
C-reactive protein increased13.09.01.0070.002398%Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.000139%Not Available
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.0010.002780%
Cardiac failure congestive02.05.01.002--Not Available
Cardiac tamponade02.06.01.0010.000208%
Cardio-respiratory arrest22.02.06.007; 02.03.04.002--Not Available
Cardiomyopathy02.04.01.001--Not Available
Cardiovascular disorder24.03.02.009; 02.01.01.001--Not Available
Cataract06.06.01.0010.001865%
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.003--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.003197%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort02.02.02.009; 22.02.08.001; 08.01.08.019--Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Choking22.02.05.0010.000799%Not Available
Cholestasis09.01.01.001--Not Available
Chromatopsia06.02.05.0010.000533%Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Circulatory collapse24.06.02.001--Not Available
Clubbing22.02.08.013; 15.03.02.006; 02.01.02.0120.000139%Not Available
Cold sweat08.01.03.024; 23.02.03.002--Not Available
Colitis07.08.01.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 20 Pages